GLYNASE PRESTAB Rx
Generic Name and Formulations:
Glyburide, micronized 1.5mg, 3mg, 6mg; scored tabs.
Indications for GLYNASE PRESTAB:
Adjunct to diet and exercise in type 2 diabetes.
Initially 1.5–3mg daily with breakfast. Debilitated: initially 0.75mg daily with breakfast. Increase by 1.5mg at weekly intervals if needed per blood glucose. Maintenance: 0.75–12mg daily in single or divided doses (consider divided doses above 6mg daily); max 12mg daily.
Initially 0.75mg daily with breakfast.
Diabetic ketoacidosis, with or without coma. Type 1 diabetes. Concomitant bosentan.
Increased risk of cardiovascular mortality. Impaired renal or hepatic function. Stress. Secondary failure may occur with extended therapy. Discontinue if jaundice or persistent rash occurs. G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine, blood glucose, and glycosylated hemoglobin. Retitrate if transfer from other glyburide containing or hypoglycemic agents (see full labeling). Elderly, debilitated, malnourished, adrenal or pituitary insufficiency, severe/prolonged exercise: increased risk of hypoglycemia. Pregnancy (Cat.B): consider using insulin instead; if glyburide needed, discontinue ≥2 weeks before delivery date. Nursing mothers: not recommended.
Sulfonylurea (2nd generation).
Elevated liver enzymes with concomitant bosentan (see Contraindications). Increased risk of hypoglycemia with concomitant alcohol or other hypoglycemics. Potentiated by NSAIDs, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, β-blockers. Antagonized by diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers and isoniazid. May be potentiated by ciprofloxacin, oral miconazole. Administer glyburide >4hrs prior to colesevelam. Disulfiram-like reaction with alcohol (rare). Monitor for 2 weeks if transferring from chlorpropamide.
Hypoglycemia, cholestatic jaundice (rare), nausea, epigastric fullness, heartburn, allergic skin reactions, photosensitivity, blood dyscrasias, hepatic porphyria, hyponatremia.
PresTab 1.5mg—100; 3mg—100, 500, 1000; 6mg—100, 500
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Smoking Promotes Disease Progression in Multiple Sclerosis
- Situation Framing, Language Can Influence Decision-Making
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- FDA: Opioid Analgesic REMS Expanded to Include Immediate-Release Products